目前美国许多厂家采用冻干后加热灭活法来消除凝血因子制剂中的1型人类免疫缺陷症病毒(HIV-1)。作者报告了他们在两年间收治的400多例使用血液制剂的病例中,有6例为使用干热灭活的因子Ⅷ浓制剂后血清抗-HIV-1阳转。对于收治的病例首先用酶免疫试验(EIA)检测血清抗-HIV-1,阳性者用免疫印迹法复测,并用EIA检测HIV-1 p24抗原。抗-HIV-1阴性病例在使用血液制剂后每6个 At present, many manufacturers in the United States use lyophilization and heat inactivation to eliminate type 1 human immunodeficiency virus (HIV-1) in clotting factor preparations. Of the more than 400 cases of blood transfusions they received in two years, they reported positive anti-HIV-1 seroconversion after using dry-inactivated factor VIII concentrates. Serum anti-HIV-1 was first detected by Enzyme Immunoassay (EIA) in patients who were treated. The positive individuals were retested by immunoblotting and the HIV-1 p24 antigen was detected by EIA. Anti-HIV-1 negative cases every 6 after using blood preparations